News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ultragenyx Announces Completion of Phase 2 Study Enrollment for UX001 in Hereditary Inclusion Body Myopathy


10/30/2012 6:52:18 AM

NOVATO, Calif., Oct. 30, 2012 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced it has completed patient enrollment in a randomized, double-blind, placebo-controlled Phase 2 study of UX001 in patients with hereditary inclusion body myopathy (HIBM). The study's primary objective is to evaluate safety, dose, and improvements in sialylation biochemistry of muscle from pre-treatment to post-treatment biopsies (pharmacodynamic endpoint). Muscle strength, clinical function and patient-reported outcomes will also be evaluated, though the study is not powered for these endpoints. A total of 45 patients between 18 and 65 years of age, with a confirmed genetic mutation for HIBM, have been randomized to placebo versus two dose levels of active drug at four clinical sites in the US and Israel.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES